99 related articles for article (PubMed ID: 23158643)
21. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
22. Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib.
Franck N; Barete S; Moguelet P; Blanchet B; Carlotti A; Ropert S; Avril MF; Francès C; Billemont B; Goldwasser F
J Clin Oncol; 2010 Nov; 28(31):e640-2. PubMed ID: 20855839
[No Abstract] [Full Text] [Related]
23. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
Regnier-Rosencher E; Lazareth H; Gressier L; Avril MF; Thervet E; Dupin N
Br J Dermatol; 2013 Oct; 169(4):934-8. PubMed ID: 23909652
[TBL] [Abstract][Full Text] [Related]
24. Acetaminophen-induced lichenoid keratosis: a new way to look at an old lesion.
Wohl Y; Gat A; Shirazi I; Brenner S
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):548-9. PubMed ID: 17373992
[No Abstract] [Full Text] [Related]
25. Fixed drug eruption due to sulphamethoxydiazine.
Fluker JL; Waugh MA
Trans St Johns Hosp Dermatol Soc; 1972; 58(1):59-61. PubMed ID: 4261024
[No Abstract] [Full Text] [Related]
26. [A patient with skin eruptions due to practolol].
Faber WR; Hulsebosch HJ; Overdijk AD; van der Upwich WG
Ned Tijdschr Geneeskd; 1976 Jan; 120(4):165-7. PubMed ID: 128703
[No Abstract] [Full Text] [Related]
27. Multifocal fixed drug eruption due to celecoxib.
Bellini V; Stingeni L; Lisi P
Dermatitis; 2009; 20(3):174-6. PubMed ID: 19470306
[No Abstract] [Full Text] [Related]
28. Venlafaxine-associated psoriasiform palmoplantar keratoderma and subungual hyperkeratosis.
Dalle S; Becuwe C; Balme B; Thomas L
Br J Dermatol; 2006 May; 154(5):999-1000. PubMed ID: 16634912
[No Abstract] [Full Text] [Related]
29. Psoriasiform fixed drug eruption caused by nimesulide.
Katoulis AC; Bozi E; Kanelleas A; Makris M; Alevizou A; Panagiotides I; Stavrianeas NG
Clin Exp Dermatol; 2009 Oct; 34(7):e360-1. PubMed ID: 19486051
[No Abstract] [Full Text] [Related]
30. Fixed drug eruption due to 'nonabsorbable' sulphonamides.
Tan RS
Proc R Soc Med; 1974 Mar; 67(3):198-200. PubMed ID: 4274420
[No Abstract] [Full Text] [Related]
31. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
Dabner M; Harvey NT; Soma A; Wood BA
Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
[No Abstract] [Full Text] [Related]
32. [Eruption of purpura compatible with vasculitis and torasemide].
Sanfélix Genovés J; Benlloch Nieto H; Verdú Tárraga R; Costa Alcaraz AM
Aten Primaria; 1998 Mar; 21(4):252-3. PubMed ID: 9607256
[No Abstract] [Full Text] [Related]
33. Localized dyskeratotic plaque with milia associated with sorafenib.
Chappell JA; Burkemper NM; Semchyshyn N
J Drugs Dermatol; 2009 Jun; 8(6):573-6. PubMed ID: 19537383
[TBL] [Abstract][Full Text] [Related]
34. Maculopapular type drug eruption caused by silodosin.
Inoue A; Sawada Y; Ohmori S; Omoto D; Haruyama S; Yoshioka M; Nisio D; Nakamura M
Allergol Int; 2016 Apr; 65(2):219-220. PubMed ID: 26806055
[No Abstract] [Full Text] [Related]
35. Ocular involvement in generalized fixed drug eruption from nimesulide.
Rubegni P; Tognetti L; Tosi GM; Flori ML; Fimiani M
Clin Exp Ophthalmol; 2013 Dec; 41(9):896-8. PubMed ID: 23448657
[No Abstract] [Full Text] [Related]
36. Targeting the adnexal epithelium: an unusual case of syringometaplasia in a patient on vemurafenib.
Yu J; Ravikumar S; Plaza JA; Troy JL; Schieke SM
Am J Dermatopathol; 2015 May; 37(5):e57-60. PubMed ID: 25839889
[TBL] [Abstract][Full Text] [Related]
37. Drug eruption associated with sulfonamide treatment of vertebral osteomyelitis in a dog.
Scott DW; Barrett RE; Tangorra L
J Am Vet Med Assoc; 1976 Jun; 168(12):1111-4. PubMed ID: 132414
[TBL] [Abstract][Full Text] [Related]
38. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops.
Mullins RJ; Lones R; Dutta B
Australas J Dermatol; 2004 May; 45(2):151-2. PubMed ID: 15068470
[No Abstract] [Full Text] [Related]
39. Multiple milia associated with use of the tyrosine kinase inhibitor dovitinib.
Baek SW; Seo YJ; Lee HJ
Australas J Dermatol; 2018 Feb; 59(1):57-58. PubMed ID: 28636150
[No Abstract] [Full Text] [Related]
40. Arbor cutis: hyperkeratotic plaque secondary to the use of imiquimod for the treatment of squamous cell carcinoma in situ.
Knabel P; Cleaver L
Dermatol Surg; 2013 Apr; 39(4):655-7. PubMed ID: 23331869
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
